BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

766 related articles for article (PubMed ID: 17068199)

  • 1. Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction, and changes in receptor phosphorylation.
    Al-Dhaheri MH; Rowan BG
    Mol Endocrinol; 2007 Feb; 21(2):439-56. PubMed ID: 17068199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
    Shah YM; Rowan BG
    Mol Endocrinol; 2005 Mar; 19(3):732-48. PubMed ID: 15528270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells].
    Meng QW; Zhao CH; Xi YH; Cai L; Sun LC; Sui GJ
    Ai Zheng; 2006 Aug; 25(8):967-73. PubMed ID: 16965676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recruitment of coactivator glucocorticoid receptor interacting protein 1 to an estrogen receptor transcription complex is regulated by the 3',5'-cyclic adenosine 5'-monophosphate-dependent protein kinase.
    Fenne IS; Hoang T; Hauglid M; Sagen JV; Lien EA; Mellgren G
    Endocrinology; 2008 Sep; 149(9):4336-45. PubMed ID: 18499756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells.
    Castoria G; Giovannelli P; Lombardi M; De Rosa C; Giraldi T; de Falco A; Barone MV; Abbondanza C; Migliaccio A; Auricchio F
    Oncogene; 2012 Nov; 31(46):4868-77. PubMed ID: 22266855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependence.
    Fujimoto N; Katzenellenbogen BS
    Mol Endocrinol; 1994 Mar; 8(3):296-304. PubMed ID: 7517003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of Estrogen Receptor α at serine 118 directs recruitment of promoter complexes and gene-specific transcription.
    Duplessis TT; Williams CC; Hill SM; Rowan BG
    Endocrinology; 2011 Jun; 152(6):2517-26. PubMed ID: 21505052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells.
    Gougelet A; Bouclier C; Marsaud V; Maillard S; Mueller SO; Korach KS; Renoir JM
    J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):71-81. PubMed ID: 15862952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The estrogen receptor (ER)alpha variant Delta5 exhibits dominant positive activity on ER-regulated promoters in endometrial carcinoma cells.
    Bryant W; Snowhite AE; Rice LW; Shupnik MA
    Endocrinology; 2005 Feb; 146(2):751-9. PubMed ID: 15528307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PKA-mediated stabilization of FoxH1 negatively regulates ERalpha activity.
    Yum J; Jeong HM; Kim S; Seo JW; Han Y; Lee KY; Yeo CY
    Mol Cells; 2009 Jul; 28(1):67-71. PubMed ID: 19711044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells.
    De Amicis F; Chiodo C; Morelli C; Casaburi I; Marsico S; Bruno R; Sisci D; Andò S; Lanzino M
    BMC Cancer; 2019 Nov; 19(1):1038. PubMed ID: 31684907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation of estrogen receptor alpha, serine residue 305 enhances activity.
    Tharakan R; Lepont P; Singleton D; Kumar R; Khan S
    Mol Cell Endocrinol; 2008 Nov; 295(1-2):70-8. PubMed ID: 18755239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase A activation of estrogen receptor alpha transcription does not require proteasome activity and protects the receptor from ligand-mediated degradation.
    Tsai HW; Katzenellenbogen JA; Katzenellenbogen BS; Shupnik MA
    Endocrinology; 2004 Jun; 145(6):2730-8. PubMed ID: 15033909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
    Alao JP; Lam EW; Ali S; Buluwela L; Bordogna W; Lockey P; Varshochi R; Stavropoulou AV; Coombes RC; Vigushin DM
    Clin Cancer Res; 2004 Dec; 10(23):8094-104. PubMed ID: 15585645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increases in estrogen receptor-alpha concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen.
    Fowler AM; Solodin N; Preisler-Mashek MT; Zhang P; Lee AV; Alarid ET
    FASEB J; 2004 Jan; 18(1):81-93. PubMed ID: 14718389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LSD1 engages a corepressor complex for the activation of the estrogen receptor α by estrogen and cAMP.
    Bennesch MA; Segala G; Wider D; Picard D
    Nucleic Acids Res; 2016 Oct; 44(18):8655-8670. PubMed ID: 27325688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.